Platelets
-
Publication Venue For
- TEG®6s system measures the contributions of both platelet count and platelet function to clot formation at the site-of-care.. 31:932-938. 2020
- Validated model of platelet slip at stenosis and device surfaces.. 31:373-382. 2020
- Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study.. 30:579-588. 2019
- Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.. 28:187-193. 2017
- First report of the point-of-care TEG: A technical validation study of the TEG-6S system.. 27:642-649. 2016
- CD40L expression in plasma of volunteers following LPS administration: A comparison between assay of CD40L on platelet microvesicles and soluble CD40L.. 26:486-490. 2015
- Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy?. 26:608-609. 2015
- Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity.. 24:166-169. 2013
- Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.. 23:274-281. 2012
- Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response.. 23:430-438. 2012
- Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study.. 21:360-367. 2010
- A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.. 20:302-315. 2009
- The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting.. 20:97-104. 2009
- Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.. 19:595-604. 2008
- Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development.. 19:239-251. 2008